Response rates in chronic-phase CML patients treated with omacetaxine
| Response . | Patients treated, n (%), N = 62 . |
|---|---|
| Hematologic response categories | |
| Complete hematologic response | 48 (77%; 95% LCL, 65%) |
| No response | 12 (19) |
| Unevaluable | 2 (3) |
| Cytogenetic response categories | |
| Major | 14 (23%; 95% LCL, 13%) |
| Complete: 0% Ph+ cells* | 10 (16) |
| Partial: > 0%-35% Ph+ cells* | 4 (6) |
| Minor | 3 (5) |
| Minimal | 10 (16) |
| No response | 23 (37) |
| Unevaluable† | 12 (19) |
| Response . | Patients treated, n (%), N = 62 . |
|---|---|
| Hematologic response categories | |
| Complete hematologic response | 48 (77%; 95% LCL, 65%) |
| No response | 12 (19) |
| Unevaluable | 2 (3) |
| Cytogenetic response categories | |
| Major | 14 (23%; 95% LCL, 13%) |
| Complete: 0% Ph+ cells* | 10 (16) |
| Partial: > 0%-35% Ph+ cells* | 4 (6) |
| Minor | 3 (5) |
| Minimal | 10 (16) |
| No response | 23 (37) |
| Unevaluable† | 12 (19) |
CML indicates chronic myeloid leukemia; and LCL, lower confidence limit.
Includes both confirmed and unconfirmed response. Unconfirmed response is based on a single bone marrow cytogenetic evaluation for patients where a confirmatory evaluation is not available.
Patients with unevaluable cytogenetic responses are those with no postbaseline bone marrow assessment.